Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004;8 Suppl 2(Suppl 2):S18-23.
doi: 10.1186/cc2847. Epub 2004 Jun 14.

Infectious and immunologic consequences of blood transfusion

Affiliations
Review

Infectious and immunologic consequences of blood transfusion

E Patchen Dellinger et al. Crit Care. 2004.

Abstract

Blood transfusions remain common practice in the critical care and surgical settings. Transfusions carry significant risks, including risks for transmission of infectious agents and immune suppression. Transmission of bacterial infections, although rare, is the most common adverse event with transfusion. The risk for transmission of viral infections has decreased over time, clearly because tests are becoming more sensitive in detecting certain viral infections such as hepatitis B, hepatitis C, and HIV. Several immunomodulatory effects are thought to be related to transfusions, and these can result in cancer recurrence, mortality, and postoperative infections. Numerous studies have been performed to examine the role of leukoreduction in decreasing these transfusion-related complications but results remain contradictory. We review the infectious risks associated with blood transfusion and the most recent data on its immunologic effects, specifically on cancer recurrence, mortality, and postoperative infections in surgical patients. We also review the use of leukoreduction in blood transfusion and its role in preventing transfusion-transmitted infections and immunomodulatory complications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts–blood transfusion. N Engl J Med. 1999;340:438–447. doi: 10.1056/NEJM199902113400606. - DOI - PubMed
    1. Ratko TA, Cummings JP, Oberman HA, Crookston KP, DeChristopher PJ, Eastlund DT, Godwin JE, Sacher RA, Yawn DH, Matuszewski KA. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41:1310–1319. doi: 10.1046/j.1537-2995.2001.41101310.x. - DOI - PubMed
    1. McAlister FA, Clark HD, Wells PS, Laupacis A. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg. 1998;85:171–178. doi: 10.1046/j.1365-2168.1998.00698.x. - DOI - PubMed
    1. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5:253–259. - PubMed
    1. Kahn RA. Diseases transmitted by blood transfusion. Hum Pathol. 1983;14:241–247. - PubMed

MeSH terms